

REFERENCES

1. จตุพล ศรีสมบูรณ์, มะเร็งปากมดลูก การวินิจฉัยและการรักษา (ภาควิชา
สูติศาสตร์และนรีเวชวิทยา คณะแพทยศาสตร์ มหาวิทยาลัยเชียงใหม่,
2547), หน้า 121-133
2. Abd el all H, Rye A, Duvillard P. p53 immunohistochemical expression of
Egyptian cervical carcinoma. *Pathol Oncol Res.* 1999; 5: 280-284
3. American Society for Colposcopy and Cervical Pathology. 2004 “*Anatomy of uterine
cervix*” [Online] Available <http://www.asccp.org/edu/practice/cervix/histology.shtm>
(2004 January 3)
4. Aoki Y, Watanabe M, Sasaki M, Sato T, Kase H, Aida H, Kurata H, and Tanaka K.
Prognostic factors and failure pattern in lymph node- negative stage IB and II
cervical carcinoma treated with radical hysterectomy and postoperative
irradiation. *Gynecol Obstet Invest.* 2001; 52: 13-17
5. Bartek J, Bartkova J, Lukas J, Staskova Z, Vojtesek B, and Lane DP.
Immunohistochemical analysis of the p53 oncoprotein on paraffin sections
using a series of novel monoclonal antibodies. *J Pathol.* 1993; 169: 27-34
6. Benedet JL, Bender H, Jones H, Ngan HY, and Pecorelli S. FIGO staging
classifications and clinical practice guidelines in the management of
gynecologic cancers. FIGO Committee on Gynecologic Oncology. *Int J
Gynecol Obstet.* 2000; 70: 209-262
7. Bosari S, Roncalli M, Viale G, Bossi P, and Coggi G. p53 immunoreactivity in
inflammatory and neoplastic diseases of the uterine cervix. *J Pathol.* 1993;
169: 425-430
8. Brate A. and Giannakakou P. The importance of p53 location: nuclear
or cytoplasmic zip code?. *Drug Resistance Update.* 2003; 313-322
9. Bremer GL, Tieboschb AT, van der Putten HW, de Haan J, and Arends JW. p53
tumor suppressor gene protein expression in cervical cancer: relationship to

- prognosis. *Eur J Obstet Gynecol Reprod Biol.* 1995; 63: 55-59
10. Chen HY, Hsu CT, Lin WC, Tsai HD, and Chang WC. Prognostic value of p53 expression in stage IB1 cervical carcinoma. *Gynecol Obstet Invest.* 2000; 49: 266-271(Abstract)
 11. Dimitrakakis C, Kymionis G, Diakomanolis E, Papaspyrou I, Rodolakis A, Arzimanoglou I, Leandros E, and Michalas S. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions. *Gynecol Oncol.* 2000; 77: 129-136
 12. Geisler JP, Geisler HE, Miller GA, Wiemann MC, Zhou Z, and Crabtree W. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months. *Gynecol Oncol.* 2000; 77: 278-82.
 13. Graflund M, Sorbe B, and Karlsson M. Immunohistochemical expression of p53, bcl-2, and p21 (WAF1/CIP1) in early cervical carcinoma: correlation with clinical outcome. *Int J Gynecol Cancer.* 2002; 12: 290-298
 14. Graflund M, Sorbe B, Karlsson M. MIB-1, p53, bcl-2, and WAF-1 expression in pelvic lymph nodes and primary tumors in early stage cervical carcinomas: correlation with clinical outcome. *Int J Oncol.* 2002; 20: 1041-1047(Abstract)
 15. Grayson W. and Cooper K. Application of Immunohistochemistry in the evaluation of neoplastic epithelial lesions of the uterine cervix and endometrium. *Cur Diagn pathol.* 2003; 9: 19-25
 16. Grossi F, Loprevite M, Chiaramondia M, Ceppa P, Pera C, Ratto GB, Serrano J, Ferrara GB, Costa R, Boni L, and Ardizzoni A. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. *Eur J Cancer.* 2003; 39: 1242-1250.
 17. Hasenburg A, Salama JK, Van TJ, Amosson C, Chiu JK, and Kieback DG. Evaluation of patients after extraperitoneal lymph node dissection and subsequent radiotherapy for cervical cancer. *Gynecol Oncol.* 2002; 84: 321-326

18. Herzog TJ. New approaches for the management of cervical cancer.
Gynecol Oncol. 2003; 90: S22-S27
19. Holm R, Skomedal H, Helland A, Kristensen G, Borresen AL, and Nesland JM.
Immunohistochemical analysis of p53 protein overexpression in
normal, premalignant, and malignant tissues of the cervix uteri.
J Pathol. 1993; 169: 21-26
20. Huang LW, Chou YY, Chao SL, Chen TJ, and Lee TTY. p53 and p21 expression
in precancerous lesions and carcinomas of the uterine cervix: Overexpression
of p53 predicts poor disease outcome. *Gynecol Oncol.* 2001; 83: 348-354
21. Hunt CR, Hale RJ, Buckley CH, and Hunt J. p53 expression in carcinoma
of cervix. *J Clin Pathol.* 1996; 49: 971-974
22. Inoue M, Fujita M., Enomoto T, Morimoto H, Monden T, Shimano T, and
Tanizawa O. Immunohistochemical analysis of p53 in gynecologic
tumors. *Am J Clin Pathol.* 1994; 102: 665-670
23. Inoue T. Prognostic significance of the depth of invasion relating to nodal
metastases, parametrial extension, and cell types. A study of 628 cases with
stage IB, IIA, and IIB cervical carcinoma. *Cancer.* 1984; 54: 3035-3042
24. Inoue T and Okumura M. Prognostic significance of parametrial extension in
patients with cervical carcinoma stages IB, IIA, and IIB. A study of 628 cases
treated by radical hysterectomy and lymphadenectomy with or without
postoperative irradiation. *Cancer.* 1984; 54: 1714-1719
25. Jain D, Srinivasan R, Patel FD, and Gupta SK. Evaluation of p53 and bcl-2
expression as prognostic markers in invasive cervical carcinoma stage IIB/III
patients treated by radiotherapy. *Gynecol Oncol.* 2003; 88: 22-28
26. Kamura T, Tsukamoto N, Tsuruchi N, Kaku T, Saito T, To N, Akazawa K, and
Nakano H. Histopathologic prognostic factors in stage IIB cervical carcinoma
treated with radical hysterectomy and pelvic node dissection- an analysis with
mathematical statistics. *Int J Gynecol Cancer.* 1993; 3: 219-225
27. Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A., Kohler MF, Bast

- RC, and Iglehart JD. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. *J Histochem Cytochem.* 1992; 40: 1047-1051(Abstract)
28. Kobierski J, Emerich J, Krolikowska B, and Majdak E. Lymph node metastasis as a prognostic factor in cervical carcinoma. *Ginekol Pol.* 2002; 73: 925-929 (Abstract)
29. Kristensen GB, Abeler VM, Risberg B, Trope C, and Bryne M. Tumor size, depth of invasion, and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma. *Gynecol Oncol.* 1999; 74: 245-251
30. Lakshmi S, Nair MB, Jayaprakash PG, Rajalekshmy TN, Nair MK, and Pillai MR. p53 protein and tumorigenesis in the uterine cervix. *Gen Diagn Pathol.* 1997; 142: 281-287(Abstract)
31. Lambkin HA, Mothersill CM, and Kelehan P. Variations in immunohistochemical detection of p53 protein overexpression in cervical carcinomas with different antibodies and methods of detection. *J Pathol.* 1994; 172: 13-18
32. Larson DM, Copeland LJ, Stringer CA, Gershenson DM, Malone JM, and Edwards CL. Recurrent cervical carcinoma after radical hysterectomy. *Gynecol Oncol.* 1988; 30: 381-387
33. Lee HK, Lee HS, Yang HK, Kim WH, Lee KU, Choe KJ, and Kim JP. Prognostic significance of Bcl-2 and p53 expression in gastric cancer. *Int J Colorectal Dis.* 2003; 18: 518-25
34. Leong A.S.-Y. Immunohistological markers for tumor prognostication. *Cur Diagn Pathol.* 2001; 7: 176-186
35. Limpaiboon T, Pooart J, Bhattarakosol P, Niruthisard S, Chantratita W, and Lulitanond V. p53 status and human papillomavirus infection in Thai women with cervical carcinoma. *Southeast Asian J Trop Med Public Health.* 2000; 31: 66-71
36. Linda J. and Carol P. “p53 : puzzle and paradine ” 2003 [online]. Available

- www.p53.genome.ad.jp/documents/about_p53.html (2003 December 25)
37. Manusirivithaya S, Isariyodom P, Charoeniam V, Pantusart A. Risk for radical hysterectomy failure. *J Med Assoc Thai*. 2001; 84: 791-797
 38. Mayall FG, Goddard H, and Gibbs AR. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections. *J Pathol*. 1992; 168: 377-381
 39. Memarzadeh S, Natarajan S, Dandade DP, Ostrzega N, Saber PA, Busuttill A, Lentz SE, and Berek JS. Lymphovascular and perineural invasion in the parametria: a prognostic factor for early-stage cervical cancer. *Obstet Gynecol*. 2003; 102: 612-619
 40. Newton M. Radical hysterectomy or radiotherapy for stage I cervical cancer. A prospective comparison with 5 and 10 years follow-up. *Am J Obstet Gynecol*. 1975; 123: 535-542
 41. Ogden GR. Methodological variations for p53 detection by immunohistochemistry. *Oral Oncol. Eur J Cancer*. 1996; 32B: 365
 42. Patanaphan V, Poussin-Rosillo H, Santa UV, and Salazar OM. Cancer of uterine cervix stage IB. Treatment results and prognostic factors. *Cancer*. 1986; 57: 866-870
 43. Peller S. Clinical implications of p53: effect on prognosis, tumor progression and chemotherapy response. *Sem Cancer Biol*. 1998; 8: 379-387
 44. Rajkumar T, Rajan S, Baruah RK, Majhi U, Selvaluxmi G, and Vasanthan A. Prognostic significance of bcl-2 and p53 protein expression in stage IIB and IIIB squamous cell carcinoma of the cervix. *Eur J Gynecol Oncol*. 1998; 19: 556-560(Abstract)
 45. Red Rock Community College. "Normal Cervix" 2003. [Online] Available <http://www.rrcconline.com/paprogram/histhtml/normal/norm016.htm> (2003 December 25)
 46. Robert J., Henry J., and Edward W. Atlas of Tumor Pathology: *Tumors of the Cervix, Vagina, and Vulva*. Washington, D.C. The American

Registry of Pathology Armed Forces Institute of Pathology. 1990

47. Roddick JW and Greenlaw RH. Treatment of cervical cancer. A randomized study of operation and radiation. *Am J Obstet Gynecol.* 1971; 109: 754-764
48. Sakuragi N, Takeda N, Hareyama H, Fujimoto T, Todo Y, Okamoto K, Takeda M, Wada S, Yamamoto R, and Fujimoto S. A multivariate analysis of blood vessel and lymph vessel invasion as predictors of ovarian and lymph node metastases in patients with cervical carcinoma. *Cancer.* 2000; 88: 2578-2583
49. Schlesselman JJ. *Case-control studies: design, conduct, analysis.* New York: Oxford University Press. 1982; 145-70
50. Schorge JO, Molpus KL, Koelliker D, Nikrui N, Goodman A, Fuller AF Jr. Stage IB and IIA cervical cancer with negative lymph nodes: the role of adjuvant radiotherapy after radical hysterectomy. *Gynecol Oncol.* 1997; 66: 31-35
51. Shao ZM, Wu J, Shen ZZ, and Nguyen M. p53 mutation in plasma DNA and its prognostic value in breast cancer patients. *Clin Cancer Res.* 2001; 7: 2222-2227
52. Stanley R., Kuma V. *Basic Pathology: Neoplasia.* United States of America. 2003; 165-188
53. Takeda N, Sakuragi N, Takeda M, Okamoto K, Kuwabara M, Negishi H, Oikawa M, Yamamoto R, Yamada H, and Fujimoto S. Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy. *Acta Obstet Gynecol Scand.* 2002; 81: 1144-1151
54. Tjalma WA, Weyler JJ, Bogers JJ. The importance of biological factors (bcl-2, bax, p53, PCNA, MI, HPV and angiogenesis) in invasive cervical cancer. *Eur J Gynecol Reprod Biol.* 2001; 97: 223-230
55. Tommasino M, Accardi R, Caldeira S, Dong W, Malanchi I, Smet A, and Zehbe I. The role of TP53 in cervical carcinogenesis. *Human Mutation.* 2003; 21: 307-312

56. Trattner M, Graf AH, Lax S, Forstner R, Dandachi N, Haas J, Pickel H, Reich O, Staudach A, and Winter R. Prognostic factors in surgically treated stage IB-IIIB cervical carcinomas with special emphasis on the importance of tumor volume. *Gynecol Oncol.* 2001; 82: 11-16
57. Vogelstein B and Kinzler KW. p53 function and dysfunction. *Cell.* 1992; 70: 523-526
58. Vujkov T, Zivaljevic M, Novakovic P, Erak M, Rajovic J, and Mandic A. Treatment protocol for cervical carcinoma. *Med Pregl.* 2002; 55: 105-108 (Abstract)
59. Wang CJ, Lai CH, Huang HJ, Hong JH, Chou HH, Huang KG, and Lin JD. Recurrent cervical carcinoma after primary radical surgery. *Am J Obstet Gynecol.* 1999; 181: 518-524
60. Webb MJ and Symmonds RE. Site of recurrence of cervical cancer after radical hysterectomy. *Am. J. Obstet. Gynecol.* 1980; 138: 813-817
61. Wester K, Wahlund E, Sundstrom C, Ranefall P, Bengtsson E, Russell PJ, Ow KT, Malmstrom PU, Busch C. Paraffin section storage and immunohistochemistry. Effect of time, temperature, fixation, and retrieval protocol with emphasis on p53 protein and MIB-1 antigen. *Appl Immunohistochem Mol Morphol.* 2000; 8: 61-70 (Abstract)
62. Woods DB, Vousden KH. Regulation of p53 function. *Exp Cell Res.* 2001; 264: 56-66
63. Wynford-Thomas D. Editorial. p53 in tumor pathology: can we trust immunohistochemistry?- Revisited. *J Pathol* 1994; 166: 1-4
64. Young B. and Heath J.W. : "Female reproductive system." In *Wheater's Functional histology*, 4 th ed. Churchill livingstone., London, pp. 357-358, 2000.